Evaluation of Prediction of Polymorphisms of DNA Repair Genes on the Efficacy of Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer: A Network Meta-Analysis
- PMID: 28520216
- DOI: 10.1002/jcb.26147
Evaluation of Prediction of Polymorphisms of DNA Repair Genes on the Efficacy of Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer: A Network Meta-Analysis
Abstract
This network meta-analysis (NMA) was conducted to compare the predictive value of 14 SNPs in eight DNA repair genes on the efficacy of platinum-based chemotherapy in patients with non-small cell lung cancer (NSCLC). These included ERCC1 (rs11615, rs3212986, rs3212948), XRCC1 (rs25487, rs25489, rs1799782), XPD (rs13181, rs1799793), XPG (rs1047768, rs17655), XPA (rs1800975), XRCC3 (rs861539), APE1 (rs3136820), and RRM1 (rs1042858). The PubMed and Cochrane library databases were reviewed from their inception to February 2017 and studies which met our inclusion criteria were included in our investigation. This network meta-analysis combines direct and indirect evidence to assess the predictive value of 14 SNPs in eight DNA repair genes on the efficacy of platinum-based chemotherapy in NSCLC. We evaluated the predictive value through the use of the odd ratios (OR) and drawing surface under the cumulative ranking curves (SUCRA). A total of 26 eligible cohort studies were enrolled in this NMA. The pairwise meta-analysis indicated that in terms of overall response ratio (ORR), ERCC1 (rs11615), XRCC1 (rs25487, rs1799782), and XPD (rs13181) polymorphisms are associated with the efficacy of platinum-based chemotherapy in NSCLC. The result of this NMA suggests that there is no significant difference in predictive value of 8 DNA repair genes on the efficacy of platinum-based chemotherapy in NSCLC patients. The rank of SUCRA values of the 14 SNPs in the eight DNA repair genes were: XPD (rs1799793)→ERCC1 (rs3212986)→XPA(rs1800975)→ERCC1(rs3212948)→XRCC1(rs25487)→XRCC3(rs861539)→APE1(rs3136820)→ERCC1(rs11615)→XRCC1(rs1799782)→RRM1(rs1042858)→XPD(rs13181)→XPG (rs1047768)→XPG(rs17655)→XRCC1(rs25489). ERCC1(rs11615), XRCC1(rs25487, rs1799782) and XPD(rs13181) polymorphisms were better predictors in evaluating the efficacy of platinum-based chemotherapy in NSCLC patients. J. Cell. Biochem. 118: 4782-4791, 2017. © 2017 Wiley Periodicals, Inc.
Keywords: DNA REPAIR GENE; NON-SMALL CELL LUNG CANCER; PLATINUM-BASED CHEMOTHERAPY; POLYMORPHISM; PREDICTION.
© 2017 Wiley Periodicals, Inc.
Similar articles
-
Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis.Med Oncol. 2011 Mar;28(1):315-21. doi: 10.1007/s12032-010-9443-1. Epub 2010 Feb 9. Med Oncol. 2011. PMID: 20143185
-
The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.Tumour Biol. 2014 Apr;35(4):2905-21. doi: 10.1007/s13277-013-1493-5. Epub 2013 Dec 13. Tumour Biol. 2014. PMID: 24338713
-
Association between DNA repair gene polymorphisms and risk of glioma: a systematic review and meta-analysis.Neuro Oncol. 2014 Jun;16(6):807-14. doi: 10.1093/neuonc/nou003. Epub 2014 Feb 4. Neuro Oncol. 2014. PMID: 24500421 Free PMC article.
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 May 23;5:CD011535. doi: 10.1002/14651858.CD011535.pub5. PMID: 33871055 Free PMC article. Updated.
-
Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis.Sci Rep. 2017 Jul 17;7(1):5593. doi: 10.1038/s41598-017-05642-0. Sci Rep. 2017. PMID: 28717179 Free PMC article.
Cited by
-
Architecture of The Human Ape1 Interactome Defines Novel Cancers Signatures.Sci Rep. 2020 Jan 8;10(1):28. doi: 10.1038/s41598-019-56981-z. Sci Rep. 2020. PMID: 31913336 Free PMC article.
-
Methodological quality evaluation of systematic reviews or meta-analyses on ERCC1 in non-small cell lung cancer: a systematic review.J Cancer Res Clin Oncol. 2017 Nov;143(11):2245-2256. doi: 10.1007/s00432-017-2516-1. Epub 2017 Sep 5. J Cancer Res Clin Oncol. 2017. PMID: 28875225 Free PMC article.
-
ERCC1 and ERCC2 Polymorphisms Predict the Efficacy and Toxicity of Platinum-Based Chemotherapy in Small Cell Lung Cancer.Pharmaceutics. 2024 Aug 25;16(9):1121. doi: 10.3390/pharmaceutics16091121. Pharmaceutics. 2024. PMID: 39339159 Free PMC article.
-
Genetic Polymorphisms and the Efficacy of Platinum-Based Chemotherapy: Review.Pharmgenomics Pers Med. 2020 Oct 8;13:427-444. doi: 10.2147/PGPM.S267625. eCollection 2020. Pharmgenomics Pers Med. 2020. PMID: 33116759 Free PMC article. Review.
-
A comprehensive analysis of metabolomics and transcriptomics in non-small cell lung cancer.PLoS One. 2020 May 6;15(5):e0232272. doi: 10.1371/journal.pone.0232272. eCollection 2020. PLoS One. 2020. PMID: 32374740 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous